Methodological requirements on clinical trials with medicinal products for the treatment of anxiety disorders;Anforderungen an klinische prüfungen mit arzneimitteln bei angststörungen

Psychopharmakotherapie

Volumn 13, Issue 6, 2006, Pages 241-247

  Broich, Karl ^a  

^a Bundesinstitut für Arzneimittel ^*  (Germany)

Author keywords

Anxiety disorders; Anxiety scales; Clinical trial; Methodological requirements; Primary endpoints

Indexed keywords

ANXIOLYTIC AGENT;

ANXIETY DISORDER; CLINICAL STUDY; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG APPROVAL; GENERALIZED ANXIETY DISORDER; HUMAN; METHODOLOGY; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RATING SCALE; REVIEW; SOCIAL PHOBIA;

EID: 33845412453     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96.
2. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 2004;65:1696-707.
3. Balon R. Developments in treatment of anxiety disorders: psychotherapy, pharmacotherapy, and psychosurgery. Depress Anxiety 2004;19:63-76.
4. Balon R. Measuring anxiety: are we getting what we need? Depress Anxiety 2005;22:1-10.
5. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995;10:73-81.
6. Bandelow B, Broocks A, Pekrun G, George A, et al. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry 2000;33:174-81.
7. Bandelow B, Zohar J, Hollander E, Kasper S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002;3:171-99.
8. Barlow JH, Ellard DR, Hainsworth JM, Jones FR, et al. A review of self-management interventions for panic disorders, phobias and obsessive-compulsive disorders. Acta Psychiatr Scand 2005;111:272-85.
9. Bartz JA, Hollander E. Is obsessive-compulsive disorder an anxiety disorder? Prog Neuropsychopharmacol Biol Psychiatry 2006;30:338-52.
10. Beneke M, Rasmus W. "Clinical Global Impressions" (ECDEU): some critical comments. Pharmacopsychiatry 1992;25:171-6.
11. Blanco C, Nissenson K, Liebowitz MR. Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment. Curr Psychiatry Rep 2001;3:273-80.
12. Broich K. Klinische Prüflingen mit Antidepressiva und Antipsychotika. Das Für und Wider von Plazebokontrollen. Bundesgesundheitsbl Gesundheitsforschung Gesundheitsschutz 2005;48:541-7.
13. Burns GL, Keortge SG, Formea GM, Sternberger LG. Revision of the Padua Inventory of obsessive compulsive disorder symptoms: distinctions between worry, obsessions, and compulsions. Behav Res Ther 1996;34:163-73.
14. CHMP. Guideline on clinical investigation of medicinal products for the treatment of obsessive compulsive disorder (OCD). EMEA, 2005.
15. CHMP. Guideline on clinical investigation of medicinal products indicated for generalized anxiety disorder (GAD). EMEA, 2005.
16. CHMP. Guideline on clinical investigation of medicinal products indicated for the treatment of panic disorder (OCD). EMEA, 2005.
17. CHMP. Concept paper on the development of a guideline on the development of medicinal products for the treatment of posttraumatic stress disorder. EMEA, 2006.
18. CHMP. Guideline on clinical investigation of medicinal products indicated for the treatment of social anxiety disorder (SAD). EMEA, 2006.
19. Clark DB, Donovan JE. Reliability and validity of the Hamilton Anxiety Rating Scale in an adolescent sample. J Am Acad Child Adolesc Psychiatry 1994;33:354-60.
20. Davidson JR, Miner CM, De Veaugh-Geiss J, Tupler LA, et al. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997;27:161-6.
21. Davidson JR, Tharwani HM, Connor KM. Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. Depress Anxiety 2002;15:75-8.
22. Deacon BJ, Abramowitz JS. The Yale-Brown Obsessive Compulsive Scale: factor analysis, construct validity, and suggestions for refinement. J Anxiety Disord 2005;19:573-85.
23. Dilling H, Mombour W, Schmidt M. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien. 5. Aufl. Bern: Huber, 2004.
24. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 2003;64(Suppl 15):40-5.
25. Dunner DL. Management of anxiety disorders: the added challenge of comorbidity. Depress Anxiety 2001;13:57-71.
26. Flint AJ. Epidemiology and comorbidity of anxiety disorders in later life: implications for treatment. Clin Neurosci 1997;4:31-6.
27. Gaudiano BA. Review: cognitive behavioural therapy is an effective treatment for depression, panic disorder, and generalised anxiety disorder, but may be less effective in severe cases. Evid Based Ment Health 2006;9:80.
28. Geffken GR, Storch EA, Gelfand KM, Adkins JW, et al. Cognitive- behavioural therapy for obsessive-compulsive disorder: review of treatment techniques. J Psychosoc Nurs Ment Health Serv 2004;42:44-51.
29. Goodman WK, Price LH. Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am 1992;15:861-9.
30. Hecker JE, Losee MC, Roberson-Nay R, Maki K. Mastery of your anxiety and panic and brief therapist contact in the treatment of panic disorder. J Anxiety Disord 2004;18:111-26.
31. Heimberg RG, Horner KJ, Juster HR, Safren SA, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999;29:199-212.
32. Hoyer J, Margraf J, Angstdiagnostik. Grundlagen und Testverfahren. Berlin: Springer, 2003.
33. Kessler RC, Berglund P, Demler O, Jin R, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
34. Kessler RC, Chiu WT, Demler O, Merikangas KR, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27.
35. Kessler RC, Demler O, Frank RG, Olfson M, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352:2515-23.
36. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001;24:19-39.
37. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002;5:193-7.
38. Kjernisted KD, Bleau P. Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry 2004;49:51S-63S.
39. Lieb R. Anxiety disorders: clinical presentation and epidemiology. Handb Exp Pharmacol 2005:(169):405-32.
40. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;15:445-52.
41. Lyneham HJ, Rapee RM. Evaluation and treatment of anxiety disorders in the general pediatric population: a clinician's guide. Child Adolesc Psychiatr Clin N Am 2005;14:845-61, x.
42. Mavissakalian M. The Fear Questionnaire: a validity study. Behav Res Ther 1986;24:83-5.
43. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990;28:487-95.
44. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88:27-45.
45. Nemeroff CB. Remission: Today's target in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2002;36(Suppl 2):5.
46. Nock MK, Kessler RC. Prevalence of and risk factors for suicide attempts versus suicide gestures: analysis of the National Comorbidity Survey. J Abnorm Psychol 2006;115:616-23.
47. Oakman J, Van Ameringen M, Mancini C, Farvolden P. A confirmatory factor analysis of a self-report version of the Liebowitz Social Anxiety Scale. J Clin Psychol 2003;59:149-61.
48. Osman A, Kopper BA, Barrios FX, Osman JR, et al. The Beck Anxiety Inventory: reexamination of factor structure and psychometric properties. J Clin Psychol 1997;53:7-14.
49. Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry 2005;66(Suppl 4):28-32.
50. Otto MW, Smits JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 2004;65(Suppl 5):34-41.
51. Perkonigg A, Wittchen HU. Epidemiologie von Angststörungen. In: Kasper S, Möller HJ (editors). Angst- und Panikerkrankungen. Jena: Fischer, 1995:137-56.
52. Radomsky AS, Ouimet AJ, Ashbaugh AR, Lavoie SL, et al. Psychometric properties of the French and English versions of the Vancouver obsessional-compulsive inventory and the symmetry ordering and arranging questionnaire. Cogn Behav Ther 2006;35:164-73.
53. Rodriguez BF, Bruce SE, Pagano ME, Spencer MA, et al. Factor structure and stability of the Anxiety Sensitivity Index in a longitudinal study of anxiety disorder patients. Behav Res Ther 2004;42:79-91.
54. Sass H, Wittchen H, Zaudig M. Diagnostisches und Statistisches Manual Psychischer Störungen (DSM-IV-TR). Göttingen: Hogrefe, 2003.
55. Schnyder U, Moergeli H. German version of Clinician-Administered PTSD Scale. J Trauma Stress 2002;15:487-92.
56. Shear K, Belnap BH, Mazumdar S, Houck P, et al. Generalized anxiety disorder severity scale (GADSS): a preliminary validation study. Depress Anxiety 2006;23:77-82.
57. Shear MK, Rucci P, Williams J, Frank E, et al. Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res 2001;35:293-6.
58. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95.
59. Simpson HB, Franklin ME, Cheng J, Foa EB, et al. Standard criteria for relapse are needed in obsessive-compulsive disorder. Depress Anxiety 2005;21:1-8.
60. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006;51:100-13.
61. Sundin EC, Horowitz MJ. Impact of Event Scale: psychometric properties. Br J Psychiatry 2002;180:205-9.
62. Weissman MM, Bland RC, Canino GJ, Greenwald S, et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994;55(Suppl):5-10.
63. Wohlfarth TD, van Zwieten BJ, Lekkerkerker FJ, Gispen-de Wied CC, et al. Antidepressants use in children and adolescents and the risk of suicide. Eur Neuropsychopharmacol 2006;16:79-83.